Bronchial Mapping (GCC 1635)
In order to better understand radiation-induced lung toxicity, the investigator proposes a novel functional avoidance approach that incorporates central as well as peripheral BSS segments in the treatment planning process in order to quantify and account for their respective radiosensitivities. Specifically, the investigator proposes a systematic study that involves acquiring pre- and post-SAbR high-resolution CT and SPECT V/Q scans from lung cancer patients who receive radiotherapy, followed by auto-segmentation of the BSS elements using virtual bronchoscopy.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 15, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Maryland, Baltimore
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patients with primary or metastatic lung lesions to be treated using stereotactic ablative radiotherapy (There is no limitation on the location or number of lesions for this study) OR Conventionally fractionated RT patients with primary or metastatic lung lesions
- Age ≥ 18 years. No gender or ethnic restrictions.
- Performance status ECOG ≥ 3
- Ability to hold breath for \~20 seconds
- Ability to understand and the willingness to sign a written informed consent.
- Any types and amounts of prior therapy will be allowed for this study.
- Maximum PTV dimension ≤ 70 mm
- Children (age \<18 years).
- Women who are pregnant, nursing, or trying to get pregnant.
- ECOG performance status \< 3
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ummc MsgccBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2025. Always confirm current availability with the study team.